Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP-104IAR in knee osteoarthritis
NCT02609126Phase 1Completed
- Sponsor
- Eupraxia Pharmaceuticals Inc.
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing EP-104IAR with Vehicle (2 arms). Primary endpoints: Peak Plasma Concentration of fluticasone propionate up to 42 weeks, Fluticasone propionate concentrations in synovial fluid up to 30 weeks and 3 more. Started Apr 2016; status: completed.
02
Drugs
EP-104IAR
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02609126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609126.